Bergen

• A randomized, open-label, Phase III trial to assess the efficacy and safety of BupiZenge compared to lidocaine for pain associated with oral … Pending
  2025-524386-24-00 5 Head and neck cancer
• Adjunctive Hyperbaric Oxygen Treatment for Patients with Necrotizing Soft-Tissue Infection (HOT-NSTI trial) Recruiting
  2025-521368-37-00 6 2026-03-27 Necrotizing soft-tissue infection
• Visugromab in Cachexia International Trial Recruiting
  2025-523533-25-00 10 2026-03-26 Cancer-associated Cachexia
• A Phase 1, Open-Label, Multicenter Study of INCB160058 in Participants With Myeloproliferative Neoplasms. Recruiting
  2024-520353-21-00 3 2026-02-24 Myeloproliferative Neoplasms
• A study to investigate the effect of adding bleximenib to standard-of-care treatment with intensive chemotherapy in patients with a specific … Recruiting
  2025-522767-15-00 5 2026-01-27 Acute Myeloid Leukemia
• A Study of Baricitinib (LY3009104) for the Delay of Stage 3 Type 1 Diabetes in At-Risk Children and Adults (BARICADE-DELAY) Recruiting
  2025-521797-34-00 5 2026-01-20 Diabetes Mellitus, Type 1
• A randomized controlled phase II, double blinded trial to investigate pulmonary function after treatment with rituximab compared to placebo … Recruiting
  2024-517667-23-00 4 2025-12-17 Granulomatous Lymphocytic Interstitial Lung Disease (GLILD)
• A study to investigate the effect of adding venetoclax to treatment with ivosidenib and azacitidine in patients with acute myeloid leukemia … Recruiting
  2024-512753-24-00 5 2025-08-05 Acute Myeloid Leukemia (AML)
• A Study to Investigate the Safety and Efficacy of Pirtobrutinib in Adults with Immune Thrombocytopenia Recruiting
  2024-518502-40-00 9 2025-07-28 Immune Thrombocytopenia
• A Phase 3, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Participants With Chronic Graft-Versus-Host Disease A … Recruiting
  2024-518973-32-00 5 2025-07-03 Chronic Graft-Versus-Host Disease
• Chemoablation or bladder resection with adjuvant chemotherapy in recurrent non-muscle invasive bladder cancer Recruiting
  2022-502221-18-00 6 2025-05-26 Recurrent non-muscle invasive bladder cancer
• Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients with FLT3-ITD Negative AML Recruiting
  2023-507936-20-00 5 2025-05-05 Acute myeloid leukemia
• A study investigating the effect of adding revumenib to treatment with venetoclax + azacitidine in patients with acute myeloid leukemia (AML … Recruiting
  2024-512733-32-00 5 2025-03-31 Acute Myeloid Leukemia (AML)
• Effect of patiromer in children under 12 years of age with high blood potassium levels Recruiting
  2023-505252-21-00 4 2025-02-14 Hyperkalemia
• A randomized study in testicular cancer without metastasis, comparing two different types of chemotherapy used to reduce the risk of relapse Recruiting
  2024-518399-29-00 5 2024-12-27 Testicular cancer
• Evaluation of Efficacy of Povetacicept in Adults With Immunoglobulin A Nephropathy (IgAN). Recruiting
  2024-514135-17-00 5 2024-11-28 Immunoglobulin A Nephropathy
• A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents with Fabry Disease Recruiting
  2022-503128-29-00 10 2024-10-08 Fabry's disease
• A Phase 2 study of DNTH103 in patients with Generalized Myasthenia Gravis Recruiting
  2024-512865-15-00 4 2024-09-03 Generalized Myasthenia Gravis
• Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re … Recruiting
  2023-504918-29-00 5 2024-08-22 Hormone receptor positive breast cancer
• Double-blind, Randomized, Placebo-controlled Study Evaluating the Safety and Efficacy of Nipocalimab in Reducing the Risk of Fetal and Neona … Recruiting
  2023-504307-88-00 5 2024-02-20 Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
• CHIP-AML22/Quizartinib sub-study: study of the safety and efficacy of quizartinib in children and adolescents with FLT3-ITD positive AML wit … Recruiting
  2023-505000-27-01 4 2023-12-29 newly diagnosed pediatric FLT3-ITD positive and NPM1 wild-type AML
• A Phase 3, Open-Label, Uncontrolled Study to Evaluate the Activity, Safety, Pharmacokinetics and Pharmacodynamics of Roxadustat for the Trea … Recruiting
  2022-501980-42-00 5 2023-12-21 Anemia associated with Chronic Kidney Disease
• VB10.16 Plus Pembrolizumab in First Line r/m HNSCC Recruiting
  2022-503055-26-00 9 2023-10-30 Unresectable recurrent or metastatic HPV16 (Human Papilloma Virus) pos
• Open-label, long-term safety, efficacy, and pharmacokinetics study of vibegron in pediatric subjects 2 years to < 18 years of age with NDO a … Recruiting
  2024-513995-16-00 10 2023-07-28 Neurogenic Detrusor Overactivity (NDO)

Showing 25–48 of 235 trials